TaiGen Biopharmaceuticals Holdings Limited (4157) Stock Price & Analysis
4157 Stock Chart & Stats
- Day’s Range
- TWD 7.39 - TWD 7.95
- 52-Week Range
- TWD 7.39 - TWD 16.40
- Previous Close
- TWD 7.89
- Volume
- N/A
- Average Volume (3M)
- 1.10M
- Market Cap
- TWD 5.56B
- Enterprise Value
- TWD 5.23B
- Total Cash (Recent Filing)
- TWD 915.27M
- Total Debt (Recent Filing)
- TWD 11.43M
- Price to Earnings (P/E)
- 37.2
- Beta
- 0.54
- Next Earnings
- Nov 18, 2026 (Est.)
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
4157 FAQ
What was TaiGen Biopharmaceuticals Holdings Limited’s price range in the past 12 months?
What is TaiGen Biopharmaceuticals Holdings Limited’s market cap?
When is TaiGen Biopharmaceuticals Holdings Limited’s upcoming earnings report date?
How were TaiGen Biopharmaceuticals Holdings Limited’s earnings last quarter?
Is TaiGen Biopharmaceuticals Holdings Limited overvalued?
Does TaiGen Biopharmaceuticals Holdings Limited pay dividends?
What is TaiGen Biopharmaceuticals Holdings Limited’s EPS estimate?
How many shares outstanding does TaiGen Biopharmaceuticals Holdings Limited have?
What happened to TaiGen Biopharmaceuticals Holdings Limited’s price movement after its last earnings report?
Which hedge fund is a major shareholder of TaiGen Biopharmaceuticals Holdings Limited?
What is the TipRanks Smart Score and how is it calculated?
Company Description
TaiGen Biopharmaceuticals Holdings Limited
TaiGen Biopharmaceuticals Holdings Limited is a global pharmaceutical firm dedicated to pioneering innovative treatments for life-altering diseases. Its robust development pipeline features several key assets. Among these is Taigexyn (Nemonoxacin), a non-fluorinated quinolone antibiotic currently being advanced for the treatment of various bacterial infections, including community-acquired pneumonia and diabetic foot infections. The company is also progressing Burixafor, a stem cell mobilizer with applications in stem cell transplantation and chemosensitization. Further contributing to its portfolio is TG-1000, an antiviral medication designed to combat influenza A, B, and the avian influenza H7N9 strain. Additionally, Furaprevir, a hepatitis C virus (HCV) protease inhibitor, is under development for managing chronic hepatitis C. Established in 2001, TaiGen Biopharmaceuticals maintains its headquarters in Taipei City, Taiwan.
- Sector
- General
- Industry
- Biotechnology
- CEO
- Kuo-Lung Huang
- Employees
- 52
- Website
- www.taigenbiotech.com
- Address
- No. 138, Xinming Road, Taipei, TP, 11470, TW
TaiGen Biopharmaceuticals Holdings Limited (4157) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |

